E. Alessandrino et al., Adverse events occurring during bone marrow or peripheral blood progenitorcell infusion: analysis of 126 cases, BONE MAR TR, 23(6), 1999, pp. 533-537
Citations number
20
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Bone marrow (BM) and/or peripheral blood progenitor cells (PBPC) given afte
r high-dose chemo-radiotherapy are commonly cryopreserved, Re-infusion of t
he thawed product can cause cardiovascular and other complications. We comp
ared two groups of adult patients receiving autologous BM or PBPC transplan
t to assess the incidence of adverse events occurring during infusion, Fift
y-one patients received BM, and 75 PBPC, The two groups were comparable in
respect of age, total volume infused, quantity of dimethylsulfoxide (DMSO)
and number of polymorphonuclear neutrophils, Patients receiving PBPC had a
higher number of nucleated cells per kg of body weight; those in the BM gro
up received a significantly greater quantity of red cells. Non-cardiovascul
ar complications occurred in 19% and 8% of patients rescued by BM and PBPC
respectively. The incidence of hypertension was 21% in the BM and 36% in th
e PBPC group, Asymptomatic hypotension was more frequent in PBPC patients (
P < 0.001). Bradyarrhythmia was noticed in two of 75 PBPC patients and in 1
4 of 51 BM patients (P < 0.001). In the former group one patient had heart
block; he died of renal failure 10 days later. Bradycardia and hemoglobinur
ia were more common in patients receiving BM where a higher concentration o
f red cells was present (P < 0.001). Since bradyarrhythmias may be a life-t
hreatening complication we advise continuous careful monitoring during infu
sion of thawed BM, The strong correlation between bradycardia and red blood
cell contamination suggests the use of purified products with a very low r
ed cell content.